Ten-Year Follow-Up of Sildenafil Use in Spinal Cord-Injured Patients with Erectile Dysfunction
Giuseppe Lombardi MD,
Angelo Macchiarella MD,
Filippo Cecconi MD,
Giulio Del Popolo MD,
Giuseppe Lombardi MD
Careggi Hospital—Neuro-urology Department, Florence, Italy
Search for more papers by this authorAngelo Macchiarella MD
Careggi Hospital—Neuro-urology Department, Florence, Italy
Search for more papers by this authorFilippo Cecconi MD
Careggi Hospital—Neuro-urology Department, Florence, Italy
Search for more papers by this authorGiulio Del Popolo MD
Careggi Hospital—Neuro-urology Department, Florence, Italy
Search for more papers by this authorGiuseppe Lombardi MD,
Angelo Macchiarella MD,
Filippo Cecconi MD,
Giulio Del Popolo MD,
Giuseppe Lombardi MD
Careggi Hospital—Neuro-urology Department, Florence, Italy
Search for more papers by this authorAngelo Macchiarella MD
Careggi Hospital—Neuro-urology Department, Florence, Italy
Search for more papers by this authorFilippo Cecconi MD
Careggi Hospital—Neuro-urology Department, Florence, Italy
Search for more papers by this authorGiulio Del Popolo MD
Careggi Hospital—Neuro-urology Department, Florence, Italy
Search for more papers by this authorGiuseppe Lombardi, MD, Via Largo Palagi 1, Florence 50141, Italy. Tel: +39-339-4909080; Fax +39-055-7948526; E-mail: [email protected]
ABSTRACT
Introduction. Data are sparse concerning the long-term effects of phosphodiesterase type 5 (PDE5) inhibitors for erectile dysfunction (ED).
Aim. To evaluate the efficacy and safety of long-term sildenafil use in subjects with ED caused by spinal cord injury (SCI).
Methods. Phase 1: From October 1998 to January 1999, 113 SCI patients with ED were given 50 mg of sildenafil after a 4-week treatment-free period. Those with a score lower than 26 on the International Index of Erectile Function (IIEF-15) and with less than 75% total successful sexual attempts the dosage of sildenafil was increased to 100 mg. Attempts were evaluated using the Sexual Encounter Profile Questions 2 and 3 (SEP2 and 3) regarding respectively the capacity to penetrate their partner and to maintain the erection after penetration. Phase 2: Only responding patients entered phase 2 where they were evaluated every 6 months. The final visit was concluded by January 2009.
Main Outcome Measures. Follow-up using the IIEF-15 questionnaire every 6 months.
Results. Seventy-five patients entered Phase 2. Thirty-eight patients were excluded, 35 of them because they did not respond to the drug. Lesions higher than T12, an incompleteness of lesions, and higher residual erection were significant predictable factors for the success of the therapy (P < 0.05). Phase 2: the most frequent reason (68.3%) for discontinuing treatment was the desire to try a new oral therapy especially for patients using 100 mg. Thirty-four individuals continued treatment, 28 of whom took 50 mg.
Conclusion. Sildenafil represents an effective and safe long-term option for SCI subjects with ED. Further investigation of long-term use of oral PDE5 inhibitors in SCI patients is needed for evaluating both factors that are determinant in the choice of a starter treatment and in detecting elements that influence the switching from initial treatment. Lombardi G, Macchiarella A, Cecconi F, and Del Popolo G. Ten-year follow-up of sildenafil use in spinal cord-injured patients with erectile dysfunction. J Sex Med 2009;6:3449–3457.
References
- 1 Courtois FJ, Charvier KF, Leriche A, Raymond DP. Sexual function in spinal cord injury men. Assessing sexual capability. Paraplegia 1993; 31: 771–84.
- 2 Courtois FJ, Goulet MC, Charvier KF, Leriche A. Posttraumatic erectile potential of spinal cord injured men: How physiologic recordings supplement subjective reports. Arch Phys Med Rehabil 1999; 80: 1268–72.
- 3 Alexander MS, Biering-Sorensen F, Bodner D, Brackett NL, Cardenas D, Charlifue S, Creasey G, Dietz V, Ditunno J, Donovan W, Elliott SL, Estores I, Graves DE, Green B, Gousse A, Jackson AB, Kennelly M, Karlsson AK, Krassioukov A, Krogh K, Linsenmeyer T, Marino R, Mathias CJ, Perkash I, Sheel AW, Shilero G, Schurch B, Sonksen J, Stiens S, Wecht J, Wuermser LA, Wyndaele JJ. International standards to document remaining autonomic function after spinal cord injury. Spinal Cord 2009; 47: 36–43. Epub 2008 Oct 28. Review.
- 4 Stone AR. The sexual needs of the injured spinal cord patient. Probl Urol 1987; 1: 529–36.
- 5 Derry FA, Dinsmore WW, Fraser M, Gardner BP, Glass CA, Maytom MC, Smith MD. Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury. Neurology 1998; 51: 1629–33.
- 6 Schmid DM, Schurch B, Hauri D. Sildenafil in the treatment of sexual dysfunction in spinal cord-injured male patients. Eur Urol 2000; 38: 184–93.
- 7 Green BG, Martin S. Clinical assessment of sildenafil in the treatment of neurogenic male sexual dysfunction: After the hype. NeuroRehabilitation 2000; 15: 101–5.
- 8 Bodner DR, Leffler B, Frost F. The role of intracavernous injection of vasoactive medications for the restoration of erection in spinal cord injured males: A three year follow up. Paraplegia 1992; 30: 118–20.
- 9 Hirsch IH, Smith RL, Chancellor MB, Bagley DH, Carsello J, Staas WE Jr. Use of intracavernous injection of prostaglandin E1 for neuropathic erectile dysfunction. Paraplegia 1994; 32: 661–4.
- 10 Kimoto Y, Iwatsubo E. Penile prostheses for the management of the neuropathic bladder and sexual dysfunction in spinal cord injury patients: Long term follow up. Paraplegia 1994; 32: 336–9.
- 11 Dietzen CJ, Lloyd LK. Complications of intracavernous injections and penile prostheses in spinal cord injured men. Arch Phys Med Rehabil 1992; 73: 652–5.
- 12 Earle CM, Seah M, Coulden SE, Stuckey BG, Keogh EJ. The use of the vacuum erection device in the management of erectile impotence. Int J Impot Res 1996; 8: 237–40.
- 13 Denil J, Ohl DA, Smythe C. Vacuum erection device in spinal cord injured men: Patient and partner satisfaction. Arch Phys Med Rehabil 1996; 77: 750–3.
- 14 Maytom MC, Derry FA, Dinsmore WW, Glass CA, Smith MD, Orr M, Osterloh IH. A two-part pilot study of sildenafil (VIAGRA) in men with erectile dysfunction caused by spinal cord injury. Spinal Cord 1999; 37: 110–6.
- 15 Giuliano F, Hultling C, El Masry WS, Smith MD, Osterloh IH, Orr M, Maytom M. Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury. Sildenafil Study Group. Ann Neurol 1999; 46: 15–21.
- 16 Ergin S, Gunduz B, Ugurlu H, Sivrioglu K, Oncel S, Gok H, Erhan B, Levendoglu F, Senocak O. A placebo-controlled, multicenter, randomized, double-blind, flexible-dose, two-way crossover study to evaluate the efficacy and safety of sildenafil in men with traumatic spinal cord injury and erectile dysfunction. J Spinal Cord Med 2008; 31: 522–31.
- 17 Ethans KD, Casey AR, Schryvers OI, MacNeil BJ. The effects of sildenafil on the cardiovascular response in men with spinal cord injury at or above the sixth thoracic level. J Spinal Cord Med 2003; 26: 222–6.
- 18 García-Bravo AM, Suàrez-Hernàndez D, Ruiz-Fernández MA, Silva González O, Bárbara-Bataller E, Méndez Suárez JL. Determination of changes in blood pressure during administration of sildenafil (Viagra) in patients with spinal cord injury and erectile dysfunction. Spinal Cord 2006; 44: 301–8.
- 19 Hultling C, Giuliano F, Quirk F, Peña B, Mishra A, Smith MD. Quality of life in patients with spinal cord injury receiving Viagra (sildenafil citrate) for the treatment of erectile dysfunction. Spinal Cord 2000; 38: 363–70.
- 20 Moemen MN, Fahmy I, Abdelaal M, Kamel I, Mansour M, Arafa MM. Erectile dysfunction in spinal cord-injured men: Different treatment options. Int J Impot Res 2008; 20: 181–7.
- 21 Hundertmark J, Esterman A, Ben-Tovim D, Austin MA, Dougherty M. The South Australian couples sildenafil study: Double-blind, parallel-group randomized controlled study to examine the psychological and relationship consequences of sildenafil use in couples. J Sex Med 2007; 4: 1126–35.
- 22 Lombardi G, Macchiarella A, Cecconi F, Del Popolo G. Efficacy and safety of medium and long-term tadalafil use in spinal cord patients with erectile dysfunction. J Sex Med 2009; 6: 535–47.
- 23 Giuliano F, Sanchez-Ramos A, Löchner-Ernst D, Del Popolo G, Cruz N, Leriche A, Lombardi G, Reichert S, Dahl P, Elion-Mboussa A, Casariego J. Efficacy and safety of tadalafil in men with erectile dysfunction following spinal cord injury. Arch Neurol 2007; 64: 1584–92.
- 24 Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–30.
- 25 American Spinal Injury Association. International standards for neurological and functional classification of spinal cord injury revised 1996. Chicago, IL: American Spinal Injury Association; 1996.
- 26 Lewis RW, Fugl-Meyer KS, Bosch R, Fugl-Meyer AR, Laumann EO, Lizza E, Martin-Morales A. Epidemiology/risk factors of sexual dysfunction. J Sex Med 2004; 1: 35–9.
- 27 Natali A, Mondaini N, Lombardi G, Del Popolo G, Rizzo M. Heavy smoking is an important risk factor for erectile dysfunction in young men. Int J Impot Res 2005; 17: 227–30.
- 28 Sánchez Ramos A, Vidal J, Jáuregui ML, Barrera M, Recio C, Giner M, Toribio L, Salvador S, Sanmartín A, De La Fuente M, Santos JF, De Juan FJ, Moraleda S, Méndez JL, Ramírez L, Casado RM. Efficacy, safety and predictive factors of therapeutic success with sildenafil for erectile dysfunction in patients with different spinal cord injuries. Spinal Cord 2001; 39: 637–43.
- 29 Musicki B, Champion HC, Becker RE, Kramer MF, Liu T, Sezen SF, Burnett AL. In vivo analysis of chronic phosphodiesterase-5 inhibition with sildenafil in penile erectile tissues: No tachyphylaxis effect. J Urol 2005; 174: 1493–6.
- 30 Carson CC. Long-term use of sildenafil. Expert Opin Pharmacother 2003; 4: 397–405.
- 31 Sheu JY, Chen KK, Lin AT, Chang YH, Wu HH, Huang WJ, Hsu YS, Kuo JY, Chung HJ, Chang LS. Long-term efficacy and safety of sildenafil for patients with erectile dysfunction. Ther Clin Risk Manag 2007; 3: 975–81.
- 32 McMurray JG, Feldman RA, Auerbach SM, Deriesthal H, Wilson N. On behalf of the Multicenter Study Group Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction. Ther Clin Risk Manag 2007; 3: 975–81.
- 33 Sato Y, Tanda H, Kato S, Onishi S, Nitta T, Koroku M. How long do patients with erectile dysfunction continue to use sildenafil citrate? Dropout rate from treatment course as outcome in real life. Int J Urol 2007; 14: 339–42; discussion 343.
- 34 Hatzichristou D, Haro JM, Martin-Morales A, Von Keitz A, Riley A, Bertsch J, Belger M, Wolka AM, Beardsworth A; EDOS Group. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: Results from the Erectile Dysfunction Observational Study. Int J Clin Pract 2007; 61: 1850–62.
- 35 Kell PD, Hvidsten K, Morant SV, Harnett JP. Bridge S Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK. BJU Int 2007; 99: 860–3.
- 36 Kimoto Y, Sakamoto S, Fujikawa K, Tachibana T, Yamamoto N, Otani T. Up-titration of vardenafil dose from 10 mg to 20 mg improved erectile function in men with spinal cord injury. Int J Urol 2006; 13: 1428–33.
- 37 Giuliano F, Rubio-Aurioles E, Kennelly M, Montorsi F, Kim ED, Finkbeiner AE, Pommerville PJ, Colopy MW, Wilkins HJ, Wachs BH; Vardenafil Study Group. Efficacy and safety of vardenafil in men with erectile dysfunction caused by spinal cord injury. Neurology 2006; 66: 210–6.
- 38 Soler JM, Previnaire JG, Denys P, Chartier-Kastler E. Phosphodiesterase inhibitors in the treatment of erectile dysfunction in spinal cord-injured men. Spinal Cord 2007; 45: 169–73.
- 39 Del Popolo G, Li Marzi V, Mondaini N, Lombardi G. Time/duration effectiveness of sildenafil versus tadalafil in the treatment of erectile dysfunction in male spinal cord-injured patients. Spinal Cord 2004; 42: 643–8.
- 40 Giuliano F, Rubio-Aurioles E, Kennelly M, Montorsi F, Kim ED, Finkbeiner AE, Pommerville PJ, Colopy MW, Wachs BH; Vardenafil Study Group. Vardenafil improves ejaculation success rates and self-confidence in men with erectile dysfunction due to spinal cord injury. Spine 2008; 33: 709–15.
- 41 Courtois F, Charvier K, Leriche A, Vézina JG, Côté I, Raymond D, Jacquemin G, Fournier C, Bélanger M. Perceived physiological and orgasmic sensations at ejaculation in spinal cord injured men. J Sex Med 2008; 5: 2419–30. Epub 2008 May 7.
- 42 Tolrà JR, Campaña JM, Ciutat LF, Miranda EF. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J Sex Med 2006; 3: 901–9.
- 43 Mittmann N, Craven BC, Gordon M, MacMillan DH, Hassouna M, Raynard W, Kaiser A, Lanctôt LK, Tarride JE. Erectile dysfunction in spinal cord injury: A cost-utility analysis. J Rehabil Med 2005; 37: 358–64.
- 44 Ljunggren C, Hedelin H, Salomonsson K, Ströberg P. Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. J Sex Med 2007; 5: 469–75.
- 45 Gacci M, Del Popolo G, Macchiarella A, Celso M, Vittori G, Lapini A, Serni S, Sandner P, Maggi M, Carini M. Vardenafil improves urodynamic parameters in men with spinal cord injury: Results from a single dose, pilot study. J Urol 2007; 178: 2040–4.
- 46 Deforge D, Blackmer J, Garritty C, Yazdi F, Cronin V, Barrowman N, Fang M, Mamaladze V, Zhang L, Sampson M, Moher D. Male erectile dysfunction following spinal cord injury: A systematic review. Spinal Cord 2006; 44: 465–73.
